India Pharma Outlook Team | Monday, 22 June 2026
Aurobindo Pharma has moved a step closer to completing its USD 250 million acquisition of Lannett Company after receiving approval from the US Federal Trade Commission (FTC).
The regulatory clearance marks a major milestone for the transaction and removes one of the biggest hurdles in the deal process.
With the FTC approval in place, Aurobindo Pharma is now expected to complete the acquisition shortly, subject to customary closing conditions and the completion of agreed divestitures.
The acquisition is expected to strengthen Aurobindo Pharma’s presence in the United States, expand its product portfolio, and enhance its manufacturing capabilities in one of the world's largest pharmaceutical markets.
FTC Clears Acquisition With Divestiture Conditions
While approving the transaction, the FTC required Aurobindo Pharma to divest four generic drug products to Quagen Pharmaceuticals. The regulator said the sale was necessary to maintain competition in specific generic medicine markets where the merger could have reduced the number of suppliers.
The products being divested include:
The FTC's decision ensures continued competition and helps prevent potential price increases for patients relying on these medicines.
Also Read: Top 10 Performing Indian Pharma Stocks This Quarter (2026)
Strategic Benefits of the Lannett Acquisition
The acquisition is expected to provide several strategic advantages for Aurobindo Pharma, particularly in the US market.
Key benefits include:
Industry observers believe the deal aligns with Aurobindo Pharma’s long-term strategy of expanding its footprint in the United States while increasing local manufacturing capacity.
The transaction is also expected to help the company reduce dependence on a limited number of products and create opportunities for future growth through a broader product mix.
Deal Expected to Close Soon
Following the FTC clearance, Aurobindo Pharma said the transaction is expected to close shortly after completing the required divestiture process and other customary closing requirements.
The acquisition was first announced as part of the company's efforts to strengthen its position in the US generics market. The addition of Lannett’s operations and manufacturing assets is expected to support future revenue growth and operational efficiency.
Market participants will now closely watch how successfully Aurobindo Pharma integrates Lannett’s business and captures expected synergies from the acquisition. The performance of the acquired product portfolio and trends in the US generic drug market will also remain key factors for investors.
Aurobindo Pharma is one of India’s leading pharmaceutical companies with a strong presence in generic medicines, active pharmaceutical ingredients (APIs), and specialty products. The company operates across more than 150 countries and has a significant footprint in the US and European markets.
Lannett is a US-based pharmaceutical manufacturer known for producing and distributing generic pharmaceutical products. The company has built a diversified portfolio across multiple therapeutic categories and operates manufacturing facilities serving the US healthcare market.
.jpg)
